Decline of Nonrecommended HIV Care in Medicare
Among Medicare beneficiaries with HIV, the proportion receiving at least one nonrecommended antiviral prescription decreased substantially from 5.1% in 2013 to 0.1% in 2021.
METHODOLOGY:
Clinical guidelines in 2017 recommended discontinuing older, more toxic antivirals in people with HIV. However, some people continue to take them due to several barriers to switching.
This cross-sectional study used a 20% random sample of traditional Medicare beneficiaries with Part-D coverage from 2013 to 2021 and categorized prescribed antivirals as nonrecommended — based on drug toxicity and the availability of more effective alternatives — the remaining being classified as preferred.
The analysis examined the proportion of beneficiaries with HIV who received at least one nonrecommended antiviral vs those who received only preferred antivirals.
TAKEAWAY:
Of the total Medicare beneficiaries with HIV, 1052 (74.1% aged < 65 years; 74.9% men) received at least one nonrecommended antiviral prescription, and 28,019 (75.9% aged < 65 years; 74.4% men) received only preferred antivirals.
Compared with beneficiaries who received only preferred antivirals, those who received nonrecommended antivirals were more likely to be from the South (45.6% vs 50.5%; standardized mean difference, 0.10).
Didanosine and nelfinavir emerged as the most frequently prescribed nonrecommended antivirals, accounting for 27.5% and 25.3% of prescriptions, respectively.
The proportion of beneficiaries receiving nonrecommended antivirals substantially declined from 5.1% in 2013 to 0.1% in 2021.
IN PRACTICE:
'Further research should assess how many beneficiaries switched to less toxic antivirals over time (rather than being censored), characteristics associated with switching to safer alternatives, alternative antivirals prescribed instead, and how more recent ART [antiretroviral therapy] guideline recommendations may influence future prescription patterns,' the authors wrote.
SOURCE:
This study was led by Jose F. Figueroa, MD, Harvard T.H. Chan School of Public Health, Boston. It was published online on May 1, 2025, in JAMA Network Open.
LIMITATIONS:
The study focused exclusively on traditional Medicare beneficiaries living with HIV, possibly limiting the generalizability of the findings to individuals with HIV covered by commercial insurance, Medicaid, or Medicare Advantage plans. HIV diagnoses relied on claims data.
DISCLOSURES:
This study was supported by grants from the National Institute on Aging, the Harvard Center for AIDS Research, and the Advancing Clinical Therapeutics Globally program. Some authors reported having financial ties with multiple foundations and pharmaceutical organizations.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Crew-10 astronauts return to Earth following five-month mission
STORY: :: NASA :: Four astronauts from NASA's Crew-10 mission return to Earth after a five-month mission :: August 9, 2025 :: San Diego, California U.S. astronauts Nichole Ayers and Anne McClain, the Crew-10 commander, boarded the gumdrop-shaped Dragon capsule on Friday afternoon along with Japanese astronaut Takuya Onishi and Russian cosmonaut Kirill Peskov ahead of a 17.5-hour trek back to Earth to a splashdown site off the California coast. The four-person crew launched to the ISS on March 14 in a routine mission that replaced the Crew-9 crew, which included NASA astronauts Butch Wilmore and Suni Williams, the astronaut pair left on the station by Boeing's Starliner capsule. NASA said they are returning to Earth with "important and time-sensitive research" conducted in the microgravity environment of the ISS during the 146-day mission. The astronauts had over 200 science experiments on their to-do list.
Yahoo
30 minutes ago
- Yahoo
Exclusive: The Body Confidence Lesson Kylie Kelce Wants Every Girl to Hear
When Kylie Kelce talks about body confidence, it's not in the glossy, vague way we sometimes hear in ad campaigns. She's speaking as a mom of four (adorable!) girls, a former Division III field hockey player, and a coach who knows how much strength — physical and emotional — it takes for young athletes to stay in the game. That's why she's partnering with Dove on its new Fans of Confidence campaign. The campaign supports Dove's Body Confident Sport program, an evidence-based curriculum for coaches designed to help girls ages 11–17 feel seen, supported, and encouraged to keep playing. More from SheKnows Kylie Kelce's 'Kitchen Phone' Just Might be the Solution We Need for Our Teens For Kelce, the message is truly personal. 'When I was a freshman in high school, I was talking to a friend of mine who was a boy, and I had bent down next to his desk, and he was like, 'Oh, your thighs are thick.' And I looked down at my legs, and I was like, 'Yeah, because I'm a field hockey player.' … That is the moment where I was like, 'Why wouldn't I have strong legs, right?' And it was so obvious to me at that point,' she recounts in an exclusive conversation with SheKnows. 'It wasn't necessarily what my body looked like, it was what it could do for me and how it benefited me in my sport, and how the idea of strength and being muscular was an asset to me as an athlete,' she continued. 'So that having that experience myself, I want to make sure that the girls that I'm coaching [and] my own daughters understand that your body is not only valued by what it looks like … in sport, no one cares, right? Like, if you're able to run for long distances, or you're able to have endurance, you're able to have strength, you're able to translate that into your sport. Nobody cares [what it looks like], and that's important. It's so important.' Kelce says the Body Confident Sport program is key to helping coaches and parents support girls in staying active. 'You have so many young girls right now quitting sports because they don't feel like their body fits it, or because they've been told that their body is not meant for that sport. I think that it just speaks volumes about Dove that they are willing to put so much into this. And I'm so, so grateful to have the opportunity, because this is something that's clear and something that's truly important to them.' As a coach, Kelce sees her role as much more than teaching skills. 'Coaches are there to make sure that the culture of the team is that of a positive and encouraging environment … to recognize how they can uplift each other, both on and off the field. And so those positive relationships with your peers are often influenced by, like I said, the culture. So as a coach, I find it super important to not only encourage body positive talk just very blatantly, but also to make sure that they feel supported, that they feel that they can continue with their sport.' At home, she's deliberate about modeling that mindset — which hasn't always come easy. 'I honestly have had to switch up the way I speak about myself,' she confesses. 'I make it a point in front of our girls to model the way I would like them to speak about themselves … We talk a lot about, like, 'Wow, look at how strong you are.' The compliments that we give are a little bit different, and I feel like they're starting to shape the way that they think about themselves.' One recent 'proud mom' moment: when Kelce's oldest daughter Wyatt told her sister Elliotte, 'Wow, you are really strong!' 'It's so simple and it's such a fleeting moment, but at the same time, I'm like, 'Yes, that was the way to say that,'' Kelce gushes. Seeing her daughters learn how to compliment each other in ways that build confidence feels like such an accomplishment For Kelce, the message she hopes to leave — with her daughters and her players — is simple: strength, support, and encouragement matter. When girls feel supported in their bodies, they stay in the game, she says — and they carry that confidence with them into every part of life. Watch Dove's moving and inspirational 'Fans of Confidence' video here. Best of SheKnows These Raw & Beautiful Breastfeeding Photos Show There's No 'Right' Way to Nurse 'But I Hate School': What To Do When Your Teen Dreads Going Back Rugged Meets Romantic in These 'Quiet Western' Names: All the Charm, None of the Grit Solve the daily Crossword
New York Times
33 minutes ago
- New York Times
Ousted F.D.A. Vaccine Chief Returns to Agency
Dr. Vinay Prasad, who led the Food and Drug Administration's vaccines and gene therapy division before resigning under pressure two weeks ago, is returning to the agency, a Department of Health and Human Services spokesman confirmed Saturday. Dr. Prasad left the F.D.A. in late July after being targeted by the right-wing activist Laura Loomer and others who criticized his decisions regarding certain medications and pointed out critical comments he had made about President Trump before joining the administration. A series of editorials published in the weeks leading up to Dr. Prasad's resignation also appeared to have contributed to the pressure on him. Those editorials found fault with his decisions to deny drug approvals and to demand a pause on a medication linked to several patient deaths. Dr. Prasad's return was an unusual instance of a federal official being allowed to rejoin the administration after being targeted by Ms. Loomer for being insufficiently loyal to the president. She has repeatedly demonstrated her influence over federal personnel decisions. His rehiring also suggests that the health secretary, Robert F. Kennedy Jr., and the F.D.A. commissioner, Dr. Marty Makary, remain influential enough in the Trump administration to employ someone who had previously expressed disdain for Mr. Trump and his followers. 'At the F.D.A.'s request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,' Andrew Nixon, a health department spokesman, said in a statement. In a post on X Saturday, Ms. Loomer called Dr. Prasad's return 'another egregious personnel decision,' describing him as a 'Marxist.' She also pledged to ramp up her campaign against other health officials she deemed 'rabid Trump haters.' Before the resignation, Mr. Kennedy and Dr. Makary had defended Dr. Prasad against the mounting attacks, even as those seeking to have him fired lobbied the White House directly with their concerns, people familiar with the conversations said. Dr. Makary called him an 'impeccable scientist,' and Mr. Kennedy told an associate he wanted Dr. Prasad at the F.D.A. in part because of his approach to vaccines, according to people familiar with the conversation. Dr. Prasad had played a key role in the decision in May to limit the use of the Covid vaccine to people over 65 and to those with medical conditions that put them at high risk for severe illness. Their advocacy fell short, though, and Dr. Prasad issued his resignation on July 29. Dr. Prasad's long-running penchant for sharp criticism of the federal health bureaucracy, often peppered with expletives, led to intense speculation about the reasons for his ouster. It was a surprise to many in medical circles when Dr. Makary said at an event with Mr. Kennedy earlier this week that he was seeking to bring Dr. Prasad back to the F.D.A. Before entering government, Dr. Prasad was an oncologist and epidemiologist at the University of California, San Francisco, where he was active on Substack, YouTube and other social media sites, often excoriating public health officials for their approaches to the pandemic and what he viewed as poor decisions by the F.D.A. After joining the agency, he attracted attention for declining to approve several drugs, including one meant to treat advanced skin cancer and another meant to treat heart conditions for patients with a rare muscle disorder. Dr. Prasad had long called on the F.D.A. to take a stronger stance against drugs with a high price tag and uncertain benefits for patients. He has taken a similar position on vaccines, saying they need more careful examination before authorization and heightened scrutiny after. In the weeks before his ouster, Dr. Prasad also called on the company Sarepta Therapeutics to stop shipping its gene therapy drugs after the deaths of two teenagers and a 51-year-old man were deemed related to the medication. The company initially refused but later conceded. Since then, the company has resumed shipments of the medication for younger patients.
